The Food and Drug Administration (FDA) has approved the first HIV prevention drug, Truveda, to help reduce the risk of HIV infection in people without the virus.
Truveda is a milestone in pre-exposure prophylaxis or PrEP HIV prevention efforts.
As part of a daily regime, Truveda has been shown to reduce new HIV-infection rates in gay and bisexual men. Rod 2.0 reports that combined in a cocktail with Viread, the regime is up to 75 percent efficient in preventing virus transfer.
The rate of new HIV infections hovers at 50,000 per year in the United States (2006 - 2009). As sold, Truveda costs around $36 a day or $14,000 a year, leaving me with the same question that Rod has: "Who will pay for the drug?"
Truveda is a milestone in pre-exposure prophylaxis or PrEP HIV prevention efforts.
As part of a daily regime, Truveda has been shown to reduce new HIV-infection rates in gay and bisexual men. Rod 2.0 reports that combined in a cocktail with Viread, the regime is up to 75 percent efficient in preventing virus transfer.
The rate of new HIV infections hovers at 50,000 per year in the United States (2006 - 2009). As sold, Truveda costs around $36 a day or $14,000 a year, leaving me with the same question that Rod has: "Who will pay for the drug?"
Comments
No comments yet. Leave a Comment